Selectively replicating adenoviruses for oncolytic therapy

Current Cancer Drug Targets

Volumn 1, Issue 2, 2001, Pages 85-107

  Yoon, Tack Kee Laurent ^a,b   Shichinohe, Toshiaki ^a,c   Laquerre, Sylvie ^d   Kasahara, Noriyuki ^a,b,c  

^a Institute for Genetic Medicine   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; ANIMAL; BIOLOGICAL MODEL; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PHYSIOLOGY; PROMOTER REGION; REGULATORY SEQUENCE; REVIEW; VIROLOGY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GENE THERAPY; GENETIC VECTORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROMOTER REGIONS (GENETICS); REGULATORY SEQUENCES, NUCLEIC ACID; VIRUS REPLICATION;

EID: 0035428004     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009013334223     Document Type: Article

References (174)

1. Robbins, P. D.; Tahara, H.; Ghivizzani, S.C, Viral Vectors for Gene Therapy. Trend. Biotechnol. 1998,16, 35-40.
2. Vile, R. G.; Russell, S. J.; Lemoine, N. R. Cancer Gene Therapy: Hard Lessons and New Courses. Gene Ther. 2000, 7, 2-8.
3. Russell, S. J. Replicating Vectors For Gene Therapy of Cancer: Risks, Limitations and Prospects. Eur. J. Cancer 1994,8, 1165-1171.
4. Kirn, D. H.; McCormick, F. Replicating Viruses as Selective Cancer Therapeutics.- Mol. Med. Today 1996, 2, 519-527.
5. Nemunaitis, J. Oncolytic Viruses. Invest. New Drugs 1999,17, 375-386.
6. Dock, G. Influence of Complicating Disease upon Leukemia. Am. J. Med. Sci. 1904, 727, 563-592.
7. Levaditi, C.; Nicolau, S. Affinité du Virus Herpetique pour les Neoplasmes Epitheliaux. Compt. Rend. Soc. Biol. 1922, 87, 498.
8. Sinkovics, J.; Horvath, J. New Developments in the Virus Therapy of Cancer: A Historical Review. Intervirology 1993, 36, 193-214.
9. Bischoff, J. R.; Kirn, D. H.; Williams, A.; Heise, C.; Horn, S.; Muna, M.; Ng, L.; Nye, J. A.; Sampson-Johannes, A.; Fattaey, A. McCormick, F. An Adenovirus Mutant that Replicates Selectively in p53-Deficient Human Tumor Cells. Science 1996, 274, 373-376.
10. Alemany, R.; Balague, C.; Curiel, D. T. Replicative Adenoviruses for Cancer Therapy.- Nat. Biotechnol. 2000,18, 723-727.
11. Heise, C.; Kirn, D. H. Replication-Selective Adenoviruses as Oncolytic Agents. J. Clin. Invest. 2000, 705, 847-851.
12. Lorence, R. M.; Rood, P. A.; Kelley, K.W. Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor-Alpha and Augmentation of its Cytotoxicity J. Natl. Cancer Inst. 1988, 80, 1305-1312.
13. Sinkovics, J. G.; Horvath, J. C. Newcastle Disease Virus (NDV): Brief History of its Oncolytic Strains. J. Clin. Virol.2000,16, 1-15.
14. Andreansky, S.; Soroceanu, L.; Flotte, E. R.; Chou, J.; Marken, J. M.; Gillespie, G. Y.; Roizman, B.Whitley, R. J. Evaluation of Genetically Engineered Herpes Simplex Viruses as Oncolytic Agents for Human Malignant Brain Tumors. Cancer Res. 1997, 57, 1502-1509.
15. Chase, M.; Chung, R. Y.Chiocca, E. A. An Oncolytic Viral Mutant that Delivers the CYP2B1 Transgene and Augments Cyclophosphamide Chemotherapy. Nat. Biotechnol. 1998,16, 444-448.
16. Walker, J. R.; McGeagh, K. G.; Sundaresan, P.; Jorgensen, T. J.; Rabkin, S. D.Martuza, R. L. Local and Systemic Therapy of Human Prostate Adenocarcinoma with the Conditionally Replicating Herpes Simplex Virus Vector G207. Hum. Gene Ther. 1999, 10, 2237-2243.
17. Kooby, D.A.; Carew, J.F.; Halterman, M.W.; Mack, I.E.; Bertino, J.R.; Blumgart, L.H.; Federoff, H.J.Fong, Y. Oncolytic Viral Therapy for Human Colorectal Cancer and Liver Métastases Using a Multi-Mutated Herpes Simplex Virus Type-1 (G207). FASEB J. 1999,13, 1325-1334.
18. Coukos, G.; Makrigiannakis, A.; Kang, E. H.; Rubin, S. C.; Albelda, S. M.; Molnar-Kimber, K. L. Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53Independent Death and is Efficacious against Chemotherapy-Resistant Ovarian Cancer. Clin. Cancer Res. 2000, 6, 3342-3353.
19. Coffey, M. C.; Strong, J. E.; Forsyth, P. A.; Lee, P. W. Reovirus Therapy of Tumors with Activated Ras Pathway. Science 1998, 252, 1332-1334.
20. Norman, K. L.; Lee, P. W. Reovirus as a Novel Oncolytic Agent. J. Clin. Invest. 2000,105, 1035-1038.
21. Balachandran, S.; Barber, G. N. Vesicular Stomatitis Virus (VSV) Therapy of Tumors. IUBMB Life 2000, 50, 135-138.
22. Stojdl, D. F.; Lichty, B.; Knowles, S.; Marius, R.; Atkins, H.; Sonenberg, N.; Bell, J. C. Exploiting TumorSpecific Defects in the Interferon Pathway with a Previously Unknown Oncolytic Virus. Nat. Med. 2000, 6, 821-825.
23. Balachandran, S.; Porosnicu, M.; Barber, G. N. Oncolytic Activity of Vesicular Stomatitis Virus is Effective against Tumors Exhibiting Aberrant p53, Ras, or Myc Function and Involves the Induction of Apoptosis. J. Virol. 2001, 75, 3474-3479.
24. Bergelson, J. M.; Cunningham, J. A.; Droguett, G.; KurtJones, E. A.; Krithivas, A.; Hong, J. S.; Horwitz, M. S.; Crowell, R. L.; Finberg, R. W. Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5. Science 1997, 275, 1320-1323.
25. Bergelson, J. M. Receptors Mediating Adenovirus Attachment and Internalization. Biochem. Pharmacol. 1999, 57, 975-979.
26. Whyte, P.; Williamson, N. M.; Harlow, E. Cellular Targets for Transformation by the Adenovirus El A Proteins. Cell 1989, 56, 67-75.
27. Wang, H. G.; Rikitake, Y.; Carter, M. C.; Yaciuk, P.; Abraham, S. E.; Zerler, B.; Moran, E. Identification of Specific Adenovirus E1A N-Terminal Residues Critical to the Binding of Cellular Proteins and to the Control of Cell Growth. J. Viral 1993, 67, 476-488.
28. Moran, E. Interaction of Adenoviral Proteins with pRB and p53. FASEB J. 1993, 7, 880-885.
29. Nevins, J. R. E2F: A Link between the Rb Tumor Suppressor Protein and Viral Oncoproteins. Science 1992, 258, 424-429.
30. Querido, E.; Teodoro, J. G.; Branton, P. E. Accumulation of p53 Induced by The Adenovirus El A Protein Requires Regions Involved in the Stimulation of DNA Synthesis. J. Virol. 1997, 71, 3526-3533.
31. Chakravarti, D.; Ogryzko, V.; Kao, H. Y.; Nash, A.; Chen, H.; Nakatani, Y.; Evans, R. M. A Viral Mechanism for Inhibition of p300 and PCAF Acetyltransferase Activity. Cell 1999, 96, 393-403.
32. Debbas, M.; White, E. Wild-type P53 Mediates Apoptosis by El A, which is Inhibited by E1B. Genes Dev. 1993, 7, 546-554.
33. Sabbatini, P.; Lin, J.; Levine, A. J.; White, E. Genes Dev. 1995,9, 2184-2192.
34. Nakajima, T.; Morita, K.; Tsunoda, H.; Imajoh-Ohmi, S.; Tanaka, H.; Yasuda, H.; Oda, K. Stabilization of p53 by Adenovirus E1A Occurs through its Amino-Terminal Region by Modification of the Ubiquitin-Proteasome Pathway. J. Biol. Chem. 1998, 275, 20036-20045.
35. Teodoro, J. G.; Shore, G. C.; Branton, P. E. Adenovirus E1A Proteins Induce Apoptosis by both p53Dependent and p53-lndependent Mechanisms. Oncogene 1995, 11, 467-474.
36. Engel, D.A.; Hardy, S.; Shenk, T. cAMP Acts in Synergy With E1A Protein to Activate Transcription of the Adenovirus Early Genes E4 and E1A. Genes. Dev. 1988, 2, 1517-1528.
37. Shen, Y.; Shenk, T. Relief of p53-Mediated Transcriptional Repression by the Adenovirus El B 19Kda Protein or the Cellular Bcl-2 Protein. Proc. Natl. Acad. Sci. USA 1994, 91, 8940-8944.
38. Sabbatini, P.; Chiou, S.K.; Rao, L.; White, E. Modulation of p53-Mediated Transcriptional Repression and Apoptosis by the Adenovirus El B 19K Protein. Mol. Cell Biol. 1995, 15, 1060-1070.
39. Man, J.; Sabbatini, P.; Perez, D.; Rao, L.; Modha, D.; White, E. The El B 19K Protein Blocks Apoptosis by Interacting with and Inhibiting the p53-Inducible and Death-Promoting Bax Protein. Genes. Dev. 1996, 10, 461-477.
40. Kao, C. C.; Yew, P. R.; Berk, A. J. Domains Required for In Vitro Association between the Cellular p53 and the Adenovirus 2 E1B 55K Proteins. Virology 1990,179, 806-814.
41. Yew, P. R.; Berk, A. J. Inhibition of p53 Transactivation Required for Transformation by Adenovirus Early IB Protein. Nature 1992, 357, 82-85.
42. Steegenga, W.T.; Riteco, N.; Jochemsen, A. G.; Fallaux, F.J.; Bos, J. L. The Large El B Protein Together with the E4orf6 Protein Target p53 for Active Degradation in Adenovirus Infected Cells. Oncogene 1998,16, 349-357.
43. Dobbelstein, M.; Roth, J. The large T Antigen of Simian Virus 40 Binds and Inactivates p53 but not p73. J. Gen. Virol. 1998, 79, 3079-3083.
44. Pipas, J. M.; Levine, A. J. Role of T Antigen Interactions with p53 in Tumorigenesis Semin. Cancer Biol.2001, 11, 23-30.
45. Scheffner, M.; Huibregtse, J. M.; Vierstra, R. D.; Howley, P. M. The HPV-16 E6 and E6-AP Complex Functions as a Ubiquitin-Protein Ligase in the Ubiquitination of p53. Cell 1993, 75, 495-505.
46. Tommasino, M.Crawford, L. Human Papillomavirus E6 and E7: Proteins which Deregulate the Cell Cycle. Bioessays 1995, 77, 509-518.
47. McCormick, F. Interactions between Adenovirus Proteins and the p53 Pathway: The Development of ONYX-015. Semin. Cancer Biol.2000, 10, 453-459.
48. Barker, D. D.; 'Berk, A. J. Adenovirus Proteins from both El B Reading Frames are Required for Transformation of Rodent Cells by Viral Infection and DNA Transfection. Virology 1987, 156, 107-121.
49. Heise, C.; Sampson-Johannes, A.; Williams, A.; McCormick, F.; Von Hoff, D. D.; Kirn, D. H. ONYX-015, an El B Gene-Attenuated Adenovirus, Causes TumorSpecific Cytolysis and Antitumoral Efficacy that can be Augmented by Standard Chemotherapeutic Agents. Nat. Med. 1997, 3, 639-645.
50. Heise, C.C.; Williams, A.; Olesch, J.; Kirn, D. H. Efficacy of A Replication-Competent Adenovirus (ONYX-015) Following Intratumoral Injection: Jntratumoral Spread ond Distribution Effects. Cancer Gene Ther. 1999, 6, 499-504.
51. Heise, C.C.; Williams, A. M.; Xue, S.; Propst, M.; Kirn, D. H. Intravenous Administration of ONYX-015, a Selectively Replicating Adenovirus, Induces Antitumoral Efficacy. Cancer Res. 1999, 59, 2623-2628.
52. Heise, C.; Ganly, I.; Kim, Y. T.; Sampson-Johannes, A.; Brown, R.; Kirn, D. Efficacy of a Replication-Selective A'denovirus Against Ovarian Carcinomatosis is Dependent on Tumor Burden, Viral Replication And P53 Status. Gene Ther.2000, 7, 1925-1929.
53. Heise, C.; Lemmon, M.; Kirn, D. Efficacy with a Replication-Selective Adenovirus Plus Cisplatin-Based Chemotherapy: Dependence on Sequencing but not p53 Functional Status or Route of Administration. Clin. Cancer Res. 2000, 6, 4908-4914.
54. Rogulski, K.R.; Freytag, S.O.; Zhang, K.; Gilbert, J.D.; Paielli, D.L.; Kirn, J.H.; Heise, C.C.; Kirn, D. H. In Vivo Antitumor Activity of ONYX-015 is Influenced by p53 Status and is Augmented by Radiotherapy. Cancer Res. 2000,60, 1193-1196.
55. You, L.; Yang, C.T.; Jablons, D. M. ONYX-015 Works Synergistically with Chemotherapy in Lung Cancer Cell Lines and Primary Cultures Freshly Made from Lung Cancer Patients. Cancer Res. 2000, 60, 1009-1013.
56. Hall, A. R.; Dix, B. R.; O'Carroll, S. J.; Braithvvaite, A. W. p53-Dependent Cell Death/Apoptosis ils Required for a Productive Adenovirus Infection. Nat. Med. 1998,4, 1068-1072.
57. Goodrum, F. D.; Ornelles, D. A. p53 Status does not Determine Outcome of El B 55-KilodaIton Mutant Adenovirus Lytic Infection. J. Virol. 1998, 72, 9479-9490.
58. Rothmann, T.; Hengstermann, A.; Whitaker, N. J.; Scheffner, M.; zur Hausen, H. Replication of ONYX-015, A Potential Anticancer Adenovirus, is Independent of P53 Status in Tumor Cells. J. Virol. 1998, 72, 9470-9478.
59. Harada, J. N.; Berk, A. J. p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication. J. Virol. 1999, 73, 5333-5344.
60. Turnell, A. S.; Grand, R. J.; Gallimore, P.H. The Replicative Capacities of Large ElB-NulI Group A and Group C Adenoviruses are Independent of Host Cell p53 Status. J. Virol. 1999, 73, 2074-2083.
61. Hay, J. G.; Shapiro, N.; Sauthoff, H.; Heitner, S.; Phupakdi, W.; Rom, W. N. Targeting the Replication of Adenoviral Gene Therapy Vectors to Lung Cancer Cells: The Importance of the Adenoviral EIB-55kD Gene. Hum. Gene Ther. 1999,10, 579-590.
62. Dix, B. R.; O'Carroll, S. J.; Myers, C.J.; Edwards, S. J.; Braithwaite, A. W. Efficient Induction of Cell Death by Adenoviruses Requires Binding of ElBSSkD and p53. Cancer Res. 2000, 60, 2666-2672.
63. Scheffner, M.; Munger, K.; Byrne, J.C.Howley, P. M. The State of the p53 and Retinoblastoma Genes in Human Cervical Carcinoma Cell Lines. Proc. Natl. Acad. Sci. USA 1991,88, 5523-5527.
64. Steegenga, W. T.; Riteco, N.; Bos, J. L. Infectivity and Expression of the Early Adenovirus Proteins are Important Regulators of Wild-Type and DeltaElB Adenovirus Replication in Human Cells. Oncogene 1999, 18, 5032-5043.
65. Vollmer, C. M.; Ribas, A.; Butterfield, L. H.; Dissette, V. B.; Andrews, K. J.; Eilber, F. C.; Montejo, L. D.; Chen, A. Y.; Hu, B.; Glaspy, J. A.; McBride, W. H.; Economou, J. S. p53 Selective and Nonselective Replication of an ElB-Deleted Adenovirus in Hepatocellular Carcinoma. Cancer Res. 1999, 59, 4369-4374.
66. Goodrum, F. D.; Ornelles, D. A. The Early Region IB 55Kilodalton Oncoprotein of Adenovirus Relieves Growth Restrictions Imposed on Viral Replication by the Cell Cycle. J. Virol. 1997, 77, 548-561.
67. Ries, S. J.; Brandts, C. H.; Chung, A. S.; Biederer, C.H.; Hann, B. C.; Lipner, E. M.; McCormick, F.; Korn, W. M. Loss of pl4ARF in Tumor Cells Facilitates Replication of the Adenovirus Mutant dl1520 (ONYX-015). Nat. Med.2000,6, 1128-1133.
68. Kamijo, T.; Weber, J. D.; Zambetti, G.; Zindy, F.; Roussel, M. F.; Sherr, C. J. Functional and Physical Interactions of the ARF Tumor Suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 1998, 95, 8292-8297.
69. Zhang, Y.; Xiong, Y.; Yarbrough, W. G. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs both the Rb and p53 Tumor Suppression Pathways. Cell 1998, 92, 725-734.
70. Pomerantz, J.; Schreiber-Agus, N.; Liégeois, N. J.; Silverman, A.; Alland, L.; Chin, L.; Poles, J.; Chen, K.; Orlow, L; Lee, H. W.; Cordon-Cardo, C.; DePinho, R. A. Cell 1998, 92, 713.
71. Sherr, C. J.; Weber, J. D. The ARF/p53 Pathway. Ctirr. Opin. Gene. Dev. 2000,10, 94-99.
72. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The Mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53Mediated Transactivation. Cell 1992,69, 1237-1245.
73. Chen, J.; Wu, X.; Lin, J. Levine, A. J. Mdm-2 Inhibits the Gl Arrest and Apoptosis Functions of the p53 Tumor Suppressor Protein. Mol. Cell Biol. 1996, 16, 2445-2452.
74. Stojdl, D. F.; Abraham, N.; Knowles, S.; Marius, R.; Brasey, A.; Lichty, B. D.; Brown, E. G.; Sonenberg, N.; Bell, J. C. The Murine Double-Stranded RNA-Dependent Protein Kinase PKR is Required for Resistance to Vesicular Stomatitis Virus. J. Virol. 2000, 74, 9580-9585.
75. Nemunaitis, J.; Cunningham, C.; Buchanan, A.; Blackburn, A.; Edelman, G.; Maples, P.; Netto, G.; Tong, A.; Randlev, B.; Olson, S.; Kirn, D. Intravenous Infusion of a Replication-Selective Adenovirus (ONYX-015) in Cancer Patients: Safety, Feasibility and Biological Activity. Gene Ther. 2001, 8, 746-759.
76. Hallenbeck, P. L.; Chang, Y. N.; Hay, C.; Golightly, D.; Stewart, D.; Lin, J.; Phipps, S.; Chiang, Y. L. A Novel Tumor-Specific Replication-Restricted Adenoviral Vector for Gene Therapy of Hepatocellular Carcinoma. Hum. Gene Ther. 1999,10, 1721-1733.
77. Rodriguez, R.; Schuur, E. R.; Lim, H.Y.; Henderson, G.A.; Simons, J. W.; Henderson, D. R. Cancer Res. 1997, 57, 25-59.
78. Yu, D. C.; Sakamoto, G. T.; Henderson, D. R. Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy. Cancer Res. 1999, 59, 1498-1503.
79. Yu, D. C.; Chen, Y.; Seng, M.; Dilley, J.; Henderson, D. R. The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts. Cancer Res. 1999, 59, 4200-4203.
80. Ganly, I.; Eckhardt, S. G.; Rodriguez, G. I.; Soutar, D. S.; Otto, R.; Robertson, A. G.; Park, O.; Gulley, M. L.; Heise, C.; Von Hoff, D. D., Kaye, S. B. A Phase I Study of Onyx-015, an E1B Attenuated Adenovirus, Administered Intratumorally to Patients with Recurrent Head and Neck Cancer. Clin. Cancer Res, 2000, 6, 798-806.
81. Habib, N. A.; Sarraf, C. E.; Mitry, R. R.; Havlik, R.; Nicholls, J.; Kelly, M.; Vernon, C. C.; Gueret-Wardle, D.; El-Masry, R.; Salama, H.; Ahmed, R.; Michail, N.; Edward, E.; Jensen, S. L. ElB-Deleted Adenovirus (dl 1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors. Hum. Gene Ther. 2001, 12, 219-226.
82. Khuri, F. R.; Nemunaitis, J.; Ganly, I.; Arseneau, J.; Tannock, I. F.; Romel, L.; Gore, M.; Ironside, J.; MacDougall, R. H.; Heise, C.; Randlev, B.; Gillenwater, A. M.; Bruso, P.; Kaye, S. B.; Hong, W. K.; Kirn, D. H. A Controlled Trial of Intratumoral ONYX-015, a Selectively-Replicating Adenovirus, in Combination with Cisplatin and 5-Fluorouracil in Patients with Recurrent Head and Neck Cancer. Nat. Med. 2000, 6, 879-885.
83. Nemunaitis, J.; Ganly, I.; Khuri, F.; Arseneau, J.; Kühn, J.; McCarty, T.; Landers, S.; Maples, P.; Romel, L.; Randlev, B.; Reid, T.; Kaye, S.; Kirn, D. Selective Replication and Oncolysis in p53 Mutant Tumors with ONYX-015, an ElB-55kD Gene-Deleted Adenovirus, in Patients with Advanced Head and Neck Cancer: A Phase II Trial. Cancer Res. 2000, 60, 6359-6366.
84. Smith, R.R.; Huebner, R.J.; Rowe, W.P.; Schatten, W. F.; Thomas, L. B. Cancer 1956, 9, 1211-1218.
85. Lamont, J. P.; Nemunaitis, J.; Kühn, J. A.; Landers, S. A.; McCarty, T. M. A Prospective Phase II Trial of ONYX015 Adenovirus and Chemotherapy in Recurrent Squamous Cell Carcinoma of the Head and Neck (The Baylor Experience). Ann. Surg. Oncol. 2000, 7, 588-592.
86. Li, Y.; Pong, R.C.; Bergelson, J. M.; Hall, M. C.; Sagalowsky, A. I.; Tseng, C. P.; Wang, Z.; Hsieh, J. T. Loss of Adenoviral Receptor Expression in Human Bladder Cancer Cells: A Potential Impact on the Efficacy of Gene Therapy. Cancer Res. 1999, 59, 325-330.
87. Li, D.; Duan, L.; Freimuth, P.; O'Malley, B. W., Jr. Variability of Adenovirus Receptor Density Influences Gene Transfer Efficiency and Therapeutic Response in Head and Neck Cancer. Clin. Cancer Res. 1999, 5, 4175-4181.
88. Pearson, A. S.; Koch, P. E.; Atkinson, N.; Xiong, M.; Finberg, R. W.; Roth, J. A.; Fang, B. Factors Limiting Adenovirus-Mediated Gene Transfer into Human Lung and Pancreatic Cancer Cell Lines, din. Cancer Res. 1999,5, 4208-4213.
89. Douglas, J. T.; Kim, M.; Sumerel, L. A.; Carey, D. E.; Curiel, D. T. Efficient Oncolysis by a Replicating Adenovirus (ad) In Vivo is Critically Dependent on Tumor Expression of Primary ad Receptors. Cancer Res. 2001,67, 813-817.
90. Mack, C. A.; Song, W. R.; Carpenter, H.; Wickham, T. J.; Kovesdi, I.; Harvey, B. G.; Magovern, C. J.; Isom, O. W.; Rosengart, T.; Falck-Pedersen, E.; Hackett, N. R.; Crystal, R.G.; Mastrangeli, A. Circumvention of AntiAdenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype. Hum. Gene Ther. 1997,8, 99-109.
91. Smith, C. A.; Woodruff, L. S.; Rooney, C.; Kitchingman, G. R. Extensive Cross-Reactivity of Adenovirus-Specific Cytotoxic T Cells. Hum. Gene Ther. 1998, 9, 1419-1427.
92. Tao, N.; Gao, G. P.; Parr, M.; Johnston, J.; Baradet, T.; Wilson, J. M.; Barsoum, J.; Fawell, S. E. Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver. Mol. Ther. 2001,3,28-35.
93. Goossens, P. H.; Havenga, M. J.; Pieterman, E.; Lemckert, A. A.; Breedveld, F. C.; Bout, A.; Huizinga, T. W. Infection Efficiency of Type 5 Adenoviral Vectors in Synovial Tissue can be Enhanced with a Type 16 Fiber. Arthritis Rheum. 2001, 44, 570-577.
94. Krasnykh, V. N.; Mikheeva, G. V.; Douglas, J. T.; Curiel, D. T. Generation of Recombinant Adenovirus Vectors with Modified Fibers for Altering Viral Tropism. J. Virol. 1996, 70, 6839-6946.
95. Stevenson, S. C.; Rollence, M.; Marshall-Neff, J.; McClelland, A. Selective Targeting of Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein. J. Viral. 1997, 71, 4782-4790.
96. Shayakhmetov, D. M.; Papayannopoulou, T.; Stamatoyannopoulos, G.; Lieber, A. Efficient Gene Transfer into Human CD34(+) Cells by a Retargeted Adenovirus Vector. J. Virol. 2000, 74, 2567-2583.
97. Curiel, D. T. Strategies to Adapt Adenoviral Vectors for Targeted Delivery. Ann. N.Y. Acad. Sci. 1999, 886, 158-171.
98. Wickham, T. J. Targeting Adenovirus. Gene Ther. 2000, 7, 110-114.
99. Shinoura, N.; Yoshida, Y.; Tsunoda, R.; Ohashi, M.; Zhang, W.; Asai, A.; Kirino, T.; Hamada, H. Highly Augmented Cytopathic Effect of a Fiber-Mutant E1BDefective Adenovirus for Gene Therapy of Gliomas. Cancer Res. 1999, 59, 3411-3416.
100. Kurihara, T.; Brough, D; E.; Kovesdi, L; Kufe, D. W. Selectivity of a Replication-Competent Adenovirus for Human Breast Carcinoma Cells Expressing the MUC1 Antigen. J. Clin. Invest. 2000, 106, 763-771.
101. Doronin, K.; Kuppusvvamy, M.; Toth, K.; Tollefson, A.E.; Krajcsi, P.; Krougliak, V.; Wold, W. S. TissueSpecific, Tumor-Selective, Replication-Competent Adenovirus Vector for Cancer Gene Therapy. J. Virol. 2001, 75, 3314-3324.
102. Hausmann, J.; Ortmann, D.; Witt, E.; Veit, M.; Scidel, W. Adenovirus Death Protein, A Transmembrane Protein Encoded in the E3 Region, is Palmitoylated at the Cytoplasmic Tail. Virology 1998, 244, 343-351.
103. Tollefson, A. E.; Scaria, A.; Hermiston, T. W.; Ryerse, J.S.; Wold, L. J.; Wold, W. S. The Adenovirus Death Protein (E3-11.6K) is Required at Very Late Stages of Infection for Efficient Cell Lysis and Release of Adenovirus from Infected Cells. J. Viral. 1996, 70, 2296-2306.
104. Alemany, R.; Lai, S.; Lou, Y. C.; Jan, H. Y.; Fang, X.; Zhang, W. W. Complementary Adenoviral Vectors for Oncolysis. Cancer Gene Ther. 1999, 6, 21-25.
105. Rancourt, C.; Piche, A.; Gomez-Navarro, J.; Wang, M.; Alvarez, R. D.; Siegal, G. P.; Fuller, G. M.; Jones, S.A.; Curiel, D. T. Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy. Clin. Cancer Res. 1999, 5, 43-50.
106. Goldsmith, K. T.; Dion, L. D.; Curiel, D. T.; Garver, R I., Jr. Trans El Component Requirements For Maximal Replication of El-Defective Recombinant Adenovirus. Virology 1998, 248, 406-419.
107. Vile, R. G.; Sunassee, K.; Diaz, R. M. Strategies for Achieving Multiple Layers of Selectivity in Gene Therapy. Mol. Med. Today 1998, 4, 84-92.
108. Babiss, L. E.; Friedman, J. M.; Darnell, J. E., Jr. Cellular Promoters Incorporated into the Adenovirus Genome: Effects of Viral Regulatory Elements on Transcription Rates and Cell Specificity of Albumin and Beta-Globin Promoters. Mol. Cell Biol. 1986, 6, 3798-3806.
109. Babiss, L.E.; Friedman, J. M.; Darnell, J. E., Jr. Cellular Promoters Incorporated into The Adenovirus Genome. Effect of Viral DNA Replication on Endogenous and Exogenous Gene Transcription. J. Mol. Biol. 1987,193, 643-650.
110. Shi, Q.; Wang, Y.; Worton, R. Modulation of the Specificity and Activity of a Cellular Promoter in an Adenoviral Vector. Hum. Gene Ther. 1997, 8, 403-410.
111. Vassaux, G.; Hurst, H. C.; Lemoine, N. R. Insulation of a Conditionally Expressed Transgene in an Adenoviral Vector. Gene Ther. 1999,6, 1192-1197.
112. Querido, E.; Marcellus, R. C.; Lai, A.; Charbonneau, R.; Teodoro, J. G.; Keiner, G.Branton, P. E. Regulation of p53 Levels by the E1B 55-Kilodalton Protein and E4orf6 in Adenovirus-Infected Cells. J. Virol. 1997, 77, 3788-3798.
113. Querido, E.; Morisson, M. R.; Chu-Pham-Dang, H.; Thirlwell, S. W.; Boivin, D.; Branton, P. E. Identification of Three Functions of the Adenovirus E4orf6 Protein that Mediate p53 Degradation by the E4orf6-ElB55K Complex. J. Virol. 2001, 75, 699-709.
114. Konig, C.; Roth, J.; Dobbelstein, M. Adenovirus Type 5 E4orf3 Protein Relieves p53 Inhibition by E1B-55Kilodalton Protein. J. Virol. 1999, 73, 2253-2262.
115. Sauthoff, H.; Heitner, S.; Rom, W. N.; Hay, J. G. Deletion of the Adenoviral Elb-19kD Gene Enhances Tumor Cell Killing of a Replicating Adenoviral Vector. Hum. Gene Ther. 2000,11, 379-388.
116. Marcellus, R. C.; Lavoie, J. N.; Boivin, D.; Shore, G. C.; Keiner, G.; Branton, P. E. The Early Region 4 orf4 Protein of Human Adenovirus Type 5 Induces P53Independent Cell Death by Apoptosis. J. Viral. 1998, 72, 7144-7153.
117. Shtrichman, R.; Sharf, R.; Barr, H.; Dobner, T.; Kleinberger, T. Induction of Apoptosis by Adenovirus E4orf4 Protein is Specific to Transformed Cells and Requires an Interaction with Protein Phosphatase 2A. Proc. Nail. Acad. Sci. USA 1999,96, 10080-10085.
118. Lavoie, J. N.; Nguyen, M.; Marcellus, R. C.; Branton, P. E.; Shore, G. C. E4orf4, a Novel Adenovirus Death Factor that Induces P53-Independent Apoptosis By A Pathway that is not Inhibited by zVAD-fmk. J. Cell Biol. 1998, 140, 637-645.
119. Babiss, L. E.; Ginsberg, H. S.; Darnell, J. E., Jr. Adenovirus El B Proteins are Required for Accumulation of Late Viral mRNA and for Effects on Cellular mRNATranslation and Transport. Mol. Cell Biol. 1985, 5, 2552-2558.
120. Bridge, E.; Keiner, G. Interaction of Adenoviral E4 and Elb Products in Late Gene Expression. Virology 1990, 174, 345-353.
121. Hayes, B. W.; Telling, G. C.; Myat, M. M.; Williams, J. F.; Flint, S. J. The Adenovirus L4 100-Kilodalton Protein is Necessary for Efficient Translation of Viral Late mRNA Species. J. Virol. 1990, 64, 2732-2742.
122. Thimmappaya, B.; Weinberger, C.; Schneider, R. J.; Shenk, T. Adenovirus VAI RNA is Required for Efficient Translation of Viral mRNAs at Late Times after Infection. Cell 1982,57, 543-551.
123. Schneider, R. J.; Weinberger, C.; Shenk, T. Adenovirus VAI RNA Facilitates the Initiation of Translation in Virus-Infected Cells. Cell 1984, 37, 291-298.
124. Schneider, R. J.; Safer, B.; Munemitsu, S. M.; Samuel, C. E.; Shenk, T. Adenovirus VAI RNA Prevents Phosphorylation of the Eukaryotic Initiation Factor 2 Alpha Subunit Subsequent to Infection. Proc. Natl. Acad. Sci. USA 1985,82, 4321-4325.
125. O'Malley, R. P.; Duncan, R. F.; Hershey, J. W.; Mathews, M. B. Modification of Protein Synthesis Initiation Factors and the Shut-Off of Host Protein Synthesis in Adenovirus-Infected Cells. Virology 1989, 168, 112-118.
126. Logan, J.; Shenk, T. Adenovirus Tripartite Leader Sequence Enhances Translation of mRNAs Late After Infection. Proc. Natl. Acad. Sci. USA 1984, 81, 3655-3659.
127. Heise, C.; Hermiston, T.; Johnson, L.; Brooks, G.; Sampson-Johannes, A.; Williams, A.; Hawkins, L.; Kirn, D. An Adenovirus E1A Mutant that Demonstrates Potent and Selective Systemic Anti-Tumoral Efficacy. Nat. Med. 2000, 6, 1134-1139.
128. Howe, J. A.; Demers, G. W.; Johnson, D.E.; Neugebauer, S. E.; Perry, S. T.; Vaillancourt, M. T.; Faha, B. Evaluation of El-Mutant Adenoviruses as Conditionally Replicating Agents for Cancer Therapy. Mol. Ther. 2000, 2, 485-495.
129. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P. S.; McDonnell, T. J.; Mitlianga, P.; Shi, Y. X.; Levin, V. A.; Yung, W. K.; Kyritsis, A. P. A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces AntiGlioma Effect In Vivo. Oncogens, 2000,19, 2-12.
130. VVildner, O.; Blaese, R. M.; Morris, J. C. Therapy of Colon Cancer with Oncolytic Adenovirus is Enhanced by the Addition of Herpes Simplex Virus-Thymidine Kinase. Cancer Res. 1999, 59, 410-413.
131. Wildner, 0.; Morris, J. C.; Vahanian, N. N.; Ford, H., Jr.; Ramsey, W. J.; Blaese, R. M. Adenoviral Vectors Capable of Replication Improve the Efficacy of Hsvtk/GCV Suicide Gene Therapy of Cancer. Gene Ther. 1999, 6, 57-62.
132. Morris, J. C. Wildner, O. Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk. Mol. Ther. 2000, /, 56-62.
133. Wildner, O.; Morris, J. C. The Role of the E1B 55 kDa Gene Product in Oncolytic Adenoviral Vectors Expressing Herpes Simplex Virus-tk: Assessment of Antitumor Efficacy and Toxicity. Cancer Res. 2000, 60, 4167-4174.
134. Wildner, O.; Morris, J. C. Therapy of Peritoneal Carcinomatosis from Colon Cancer with Oncolytic Adenoviruses. J. Gen. Med. 2000, 2, 353-360.
135. Freytag, S. O.; Rogulski, K. R.; Paielli, D. L.; Gilbert, J. D.; Kirn, J. H. A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy. Hum. Gene Ther. 1998, 9, 1323-1333.
136. Rogulski, K. R.; Wing, M. S.; Paielli, D. L.; Gilbert, J. D.; Kirn, J. H.; Freytag, S. O. Double Suicide Gene Therapy Augments the Antitumor Activity of a Replication-Competent Lytic Adenovirus through Enhanced Cytotoxicity and Radiosensitization. Hum. Gene Ther. 2000, 11, 67-76.
137. Chirmule, N.; Propert, K.; Magosin, S.; Qian, Y.; Qian, R.; Wilson, J. Immune Responses to Adenovirus and Adeno-Associated Virus in Humans. Gene Ther. 1999, 6, 1574-1583.
138. Yei, S.; Mittereder, N.; Tang, K.; O'Sullivan, C.; Trapnell, B. C. Gene Ther. 1994,1, 192-200.
139. Yang, Y.; Li, Q.; Ertl, H. C.; Wilson, J. M. Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses. J. Yirol. 1995, 69, 2004-2015.
140. Schulick, A. H.; Vassalli, G.; Dunn, P. F.; Dong, G.; Rade, J. J.; Zamarron, C.; Dichek, D. A. Established Immunity Precludes Adenovirus-Mediated Gene Transfer in Rat Carotid Arteries. Potential for Immuno-suppression and Vector Engineering to Overcome Barriers of Immunity. J. Clin. Invest. 1997, 99, 209-219.
141. Molnar-Kimber, K. L.; Sterman, D. H.; Chang, M.; Rang, E. H.; ElBash, M.; Lanuti, M.; Elshami, A.; Gelfand, K.; Wilson, J. M.; Kaiser, L. R.; Albelda, S. M. Impact of Preexisting and Induced Humoral and Cellular Immune Responses in an Adenovirus-Based Gene Therapy Phase I Clinical Trial for Localized Mesothelioma. Hum. Gene Ther. 1998, 9, 2121-2133.
142. Yen, N.; loannides, C. G.; Xu, K.; Swisher, S. G.; Lawrence, D. D.; Kemp, B. L.; El-Naggar, A. K.; Cristiano, R. J.; Fang, B.; Glisson, B. S.; Hong, W. K.; Khuri, F. R.; Kurie, J. M.; Lee, J. J.; Lee, J. S.; Merritt, J. A.; Mukhopadhyay, T.; Nesbitt, J. C.; Nguyen, D.; PerezSoler, R.; Pisters, K. M.; Putnam, J. B., Jr.; Schrump, D. S.; Shin, D. M.; Walsh, G. L.; Roth, J. A. Cellular and Humoral Immune Responses to Adenovirus and p53 Protein Antigens in Patients Following Intratumoral Injection of an Adenovirus Vector Expressing WildType. p53 (Ad-p53). Cancer Gene Ther. 2000, 7, 530-536.
143. Yang, Y.; Trinchieri, G.; Wilson, J. M. Recombinant II12 Prevents Formation of Blocking IgA Antibodies to Recombinant Adenovirus and Allows Repeated Gene Therapy to Mouse Lung. Nat. Med. 1995,1, 890-893.
144. Ilan, Y.; Jona, V. K.; Sengupta, K.; Davidson, A.; Horwitz, M. S.; Roy-Chowdhury, N.; Roy-Chowdhury, J. Transient Immunosuppression with FK506 Permits Long-Term Expression of Therapeutic Genes Introduced into the Liver Using Recombinant Adenoviruses in the Rat. Hepatology 1997, 26, 949-956.
145. Bouvet, M.; Fang, B.; Ekmekcioglu, S.; Ji, L.; Bucana, C. D.; Hamada, K.; Grimm, E. A., Roth, J. A. Suppression of the Immune Response to an Adenovirus Vector and Enhancement of Intratumoral Transgene Expression by Low-Dose Etoposide. Gene Ther. 1998,5, 189-195.
146. Kuriyama, S.; Tominaga, K.; Kikukawa, M.; Tsujimoto, T.; Nakatani, T.; Tsujinoue, H.; Okuda, H.; Nagao, S.; Mitoro, A.; Yoshiji, H.; Fukui, H. Transient Cyclophosphamide Treatment Before Intraportal Readministration of an Adenoviral Vector Can Induce Re-Expression of the Original Gene Construct In Rat Liver. Gene Ther. 1999, 6, 749-757.
147. Jooss, K.; Turka, L. A.; Wilson, J. M. Blunting of Immune Responses to Adenoviral Vectors in Mouse Liver and Lung with CTLA4Ig. Gene Ther. 1998, 5, 309-319.
148. Ikeda, K.; Ichikawa, T.; Wakimoto, H.; Silver, J. S.; Deisboeck, T.S.; Finkelstein, D.; Harsh, G. R. T.; Louis, D. N.; Bartus, R. T.; Hochberg, F. H.; Chiocca, E. A. Oncolytic Virus Therapy of Multiple Tumors in the Brain Requires Suppression of Innate and Elicited Antiviral Responses. Nat. Med. 1999, 5, 881-887.
149. Chen, Y.; Yu, D.C.; Charlton, D.; Henderson, D. R. PreExistent Adenovirus Antibody Inhibits Systemic Toxicity And Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy. Hum. Gene Ther. 2000, 11, 1553-1567.
150. Yang, Y.; Ertl, H. C.; Wilson, J. M. MHC Class IRestricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with El-Deleted Recombinant Adenoviruses. Immunity 1994, 7, 433-442.
151. Yang, Y.; Xiang, Z.; Ertl, H.C.VVilson, J. M. Upregulation of Class I Major Histocompatibility Complex Antigens by Interferon Gamma is Necessary for T-Cell-Mediated Elimination of Recombinant Adenovirus-Infected Hepatocytes In Vivo. Proc. Natl. Acad. Sci. USA 1995,92, 7257-7261.
152. DeMatteo, R. P.; Yeh, H.; Friscia, M.; Caparrelli, D.; Burke, C.; Desai, N.; Chu, G.; Markmann, J. F.; Râper, S. E.; Barker, C. F. Cellular Immunity Delimits Adenoviral Gene Therapy Strategies for the Treatment of Neoplastic Diseases. Ann. Surg. Oncol. 1999, 6, 88-94.
153. Chan, S. Y.; Li, K.; Piccotti, J. R.; Louie, M. C.; Judge, T. A.; Turka, L. A.; Eichwald, E. J.; Bishop, D. K. TissueSpecific Consequences of the Anti-Adenoviral Immune Response: Implications for Cardiac Transplants. Nat. Med. 1999,5, 1143-1149.
154. Dewey, R. A.; Morrissey, G.; Cowsill, C. M.; Stone, D.; Bolognani, F.; Dodd, N. J.; Southgate, T. D.; Klatzmann, D.; Lassmann, H.; Castro, M. G.; Lowenstein, P. R. Chronic Brain Inflammation and Persistent Herpes Simplex Virus 1 Thymidine Kinase Expression in Survivors of Syngeneic Glioma Treated by AdenovirusMediated Gene Therapy: Implications for Clinical Trials. Nat. Med. 1999,5, 1256-1263.
155. Geutskens, S. B.; van der Eb, M. M.; Plomp, A. C.; Jonges, L. E.; Cramer, S. J.; Ensink, N. G.; Kuppen, P. J.; Hoeben, R. C. Recombinant Adenoviral Vectors Have Adjuvant Activity and Stimulate T Cell Responses against Tumor Cells. Gene Ther. 2000, 7, 1410-1416.
156. Chen, P. W.; Wang, M.; Bronte, V.; Zhai, Y.; Rosenberg, S. A.; Restifo, N. P. Therapeutic Antitumor Response after Immunization with a Recombinant Adenovirus Encoding a Model Tumor-Associated Antigen. J. Immunol. 1996, 756, 224-231.
157. Cao, X.; Ju, D. W.; Tao, Q.; Wang, J.; Wan, T.; Wang, B. M.; Zhang, W.; Hamada,- H. Adenovirus-Mediated GMCSF Gene and Cytosine Deaminase Gene Transfer Followed by 5-Fluorocytosine Administration Elicit More Potent Antitumor Response in Tumor-Bearing Mice. Gene Ther. 1998, 5, 1130-1136.
158. Kikuchi, T.; Crystal, R. G. Anti-Tumor Immunity Induced by In Vivo Adenovirus Vector-Mediated Expression of CD40 Ligand in Tumor Cells. Hum. Gene Ther. 1999, 10, 1375-1387.
159. Felzmann, T.; Ramsey, W. J.; Blaese, R. M. Anti-Tumor Immunity Generated by Tumor Cells Engineered no Express B7-1 via Retroviral or Adenoviral Gene Transfer. Cancer Lett. 1999, 735, 1-10.
160. Bowman, L.; Grossmann, M.; Rill, D.; Brown, M.; Zhong, W.Y.; Alexander, B.; Leimig, T.; Coustan-Smith, E.; Campana, D.; Jenkins, J.; Woods, D.; Kitchingman, G.; Vanin, E.; Brenner, M. IL-2 Adenovector-Transduced Autologous Tumor Cells Induce Antitumor Immune Responses in Patients with Neuroblastoma. Blood 1998, 92, 1941-1949.
161. Felzmann, T.; Ramsey, W. J.; Blaese, R. M. Characterization of the Antitumor Immune Response Generated by Treatment of Murine Tumors with Recombinant Adenoviruses Expressing HSVtk, IL-2, IL6 or B7-1. Gene Ther. 1997, 4, 1322-1329.
162. Hirschowitz, E. A.; Crystal, R. G. Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Métastases. Am. J. Respir. Cell Mol Biol. 1999, 20, 935-941.
163. Chen, S. H.; Pham-Nguyen, K. B.; Martinet, O.; Huang, Y.; Yang, W.; Thung, S. K; Chen, L.; Mittler, R.; Woo, S. L. Rejection of Disseminated Métastases of Colon Carcinoma by Synergism of IL-12 Gene Therapy and 41BB Costimulation. Mol. Ther. 2000, 2, 39-46.
164. Zhang, J. F.; Hu, C.; Geng, Y.; Scim, J.; Klein, S. B.; Orazi, A.; Taylor, M. W. Treatment of a Human Breast Cancer Xenograft with an Adenovirus Vector Containing an Interferon Gene Results in Rapid Regression due to Viral Oncolysis and Gene Therapy. Proc. Natl. Acad. Sci. USA 1996,93, 4513-4518.
165. Motoi, F.; Sunamura, M.; Ding, L.; Duda, D.G.; Yoshida, Y.; Zhang, W.; Matsuno, S.; Hamada, H. Effective Gene Therapy for Pancreatic Cancer by Cytokines Mediated by Restricted Replication-Competent Adenovirus. Hum. Gene Ther. 2000,11, 223-235.
166. Mullbacher, A. Viral Escape from Immune Recognition: Multiple Strategies of Adenoviruses. Immunol. Cell Biol. 1992, 70, 59-63.
167. Wold, W. S. Adenovirus Genes that Modulate the Sensitivity of Virus-Infected Cells to Lysis by TNF. J. Cell. Biochem. 1993, 53, 329-335.
168. Ginsberg, H. S. The Ups and Downs of Adenovirus Vectors. Bull. NY Acad. Med. 1996, 73, 53-58.
169. Jefferies, W.A.; Burgert, H. G. E3/19K from Adenovirus 2 is an Immunosubversive Protein that Binds to a Structural Motif Regulating the Intracellular Transport of Major Histocompatibility Complex Class I Proteins. J. Exp. Med. 1990, 772, 1653-1664.
170. Krajcsi, P.; Dimitrov, T.; Hermiston, T. W.; Tollefson, A. E.; Ranheim, T. S.; Vande Pol, S. B.; Stephenson, A. H.; Wold, W. S. The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, which Independently Inhibit Tumor Necrosis Factor (TNF)Induced Apoptosis, also Independently Inhibit TNFInduced Release of Arachidonic Acid. J. Virol. 1996, 70, 4904-4913.
171. Dimitrov, T.; Krajcsi, P.; Hermiston, T.W.; Tollefson, A.E.; Hannink, M.; Wold, W. S. Adenovirus E310.4K/14.5K Protein Complex Inhibits Tumor Necrosis Factor-Induced Translocation of Cytosolic Phospholipase A2 to Membranes. J. Virol. 1997, 71, 2830-2837.
172. Shisler, J.; Yang, C.; Walter, B.; Ware, C. E.; Gooding, L. R. The Adenovirus E3-10.4K/14.5K Complex Mediates Loss of Cell Surface Fas (CD95) and Resistance to FasInduced Apoptosis. J, Virol. 1997, 71, 8299-8306.
173. Benedict, C. A.; Norris, P. S.; Prigozy, T. I.; Bodmer, J. L.; Mahr, J. A.; Garnett, C. T.; Martinen, F.; Tschopp, J.; Gooding, L. R.; Ware, C. F. Three Adenovirus E3 Proteins Cooperate to Evade Apoptosis by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor-1 and -2. J. Biol. Chem. 2000. 27(5, 3270-3278.
174. Doronin, K.; Toth, K.; Kuppuswamy, M.; Ward, P.; Tollefson, A. E.; Wold, W. S. Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein. J. Virol. 2000, 74, 6147-6155.